Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998
AIDSPublished 1 December 1999
Marianne Savès, Stéphanie Vandentorren, V. Daucourt, Catherine Marimoutou, M. Dupon, Patrice Couzigou
Citations146
SJR quartileQ1
SJR score1.21
SNIP0.90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Hepatic cytolysis is more frequent among patients treated with HAART than with two NRTIs, and co-infections with hepatitis B virus or hepatitis C virus may modify the management of HIV-infected patients treated by HAART.
Abstract
Hepatic cytolysis is more frequent among patients treated with HAART than with two NRTIs. Hepatitis B and C are the major risk factors after initiation of HAART or treatment with NRTIs. Co-infections with hepatitis B virus or hepatitis C virus may modify the management of HIV-infected patients treated by HAART.
Keywords
Immunology and MicrobiologyMedicine
New England Journal of MedicineDeclining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
9,465 Citations1998Frank J. Palella, Kathleen M. Delaney +6 more
The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
The LancetClinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
933 Citations1999Bruno Ledergerber, Matthias Egger +10 more
The rate of virological failure of HAART was high among patients with a history of antiretroviral treatment, but the probability of clinical progression was low even in patients with viral rebound.
Nature MedicineThe hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response
849 Citations1996Barbara Rehermann, Carlo Ferrari +2 more
The results suggest that sterilizing immunity to HBV frequently fails to occur after recovery from acute hepatitis and that traces of virus can maintain the CTL response for decades following clinical recovery, apparently creating a negative feedback loop that keeps the virus under control, perhaps for life.
AIDSVirological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
277 Citations1997Gerd Fätkenheuer, Albert Theisen +11 more
An unexpectedly high rate of virological treatment failure of protease inhibitor therapy was found in an unselected cohort of HIV-infected patients in two German tertiary care treatment centres.
AIDSHepatotoxicity after introduction of highly active antiretroviral therapy
200 Citations1998Rafael Rodrı́guez-Rosado, Javier García‐Samaniego +1 more
The Journal of Infectious DiseasesImpact of Treatment with Human Immunodeficiency Virus (HIV) Protease Inhibitors on Hepatitis C Viremia in Patients Coinfected with HIV
190 Citations1998O. T. Rutschmann, Francesco Negro +4 more
The Lancet1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
184 Citations1998Brian Gazzard, Graeme Graeme
The BHIVA guidelines are updated with a consensus drawn from a wide range of UK medical opinion, and data from two large clinical endpoint studies have been presented that show superior clinical benefit for the use of triple therapy compared with dual therapy.
The LancetRestoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
171 Citations1997Andrew Carr, David A. Cooper
Clinical Infectious DiseasesRapidly Evolving Hepatitis C Virus–Related Cirrhosis in a Human Immunodeficiency Virus–Infected Patient Receiving Triple Antiretroviral Therapy
115 Citations1998Hervé Zylberberg, Gilles Pialoux +4 more
An unusual case of rapidly evolving HCV-related cirrhosis that paralleled restoration of immune status in an HIV-infected patient is described and the possible link between such a severe course of hepatitis C and anti-HIV triple therapy is discussed.
The LancetSevere hepatitis in three AIDS patients treated with indinavir
115 Citations1997Norbert Bräu, Howard L. Leaf +2 more
Clinical Infectious DiseasesTritherapy for Human Immunodeficiency Virus Infection Does Not Modify Replication of Hepatitis C Virus in Coinfected Subjects
93 Citations1998Hervé Zylberberg, Marie‐Laure Chaix +6 more
Antiretroviral tritherapy seems to modify neither the biological activity of HCV-related chronic hepatitis nor the HCV load, despite immune restoration, and Hepatic histopathologic analysis is warranted to assess the impact of immune restoration on liver lesions.
HepatologyA Prospective, Community–Based Evaluation of Liver Enzymes in Individuals With Hepatitis C After Drug Use
90 Citations1999Thomas V. Inglesby, Rudra Rai +5 more
Because serum ALT levels have high visit‐to‐visit variability, single assessments should not be used to manage HCV‐infected individuals and further investigation is needed to ascertain the correlation of serial ALT trends with important disease outcomes.
BMJPrevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine
55 Citations1996F. Saillour, François Dabis +10 more
The results favour the hypothesis that hepatitis C virus is sexually transmitted much less commonly than either HIV or hepatitis B virus.
Journal of Acquired Immune Deficiency Syndromes & Human RetrovirologyRapid Change in the Use of Antiretroviral Agents and Improvement in a Population of HIV-Infected Patients: France, 1995 to 1997
44 Citations1998Rosemary Dray‐Spira, Catherine Marimoutou +3 more
Over this 3-year period, physicians prescribed antiretroviral treatments more and more frequently, and triple combination therapy with PI is now common practice in France.